)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Gyre Therapeutics (GYRE) investor relations material
Gyre Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary7 Nov, 2025
Executive summary
Q3 2025 revenue rose 20% year-over-year to $30.6 million, driven by ETUARY®, Etorel®, and Contiva® sales and new product launches.
GAAP net income doubled to $5.9 million for Q3 2025, with net income attributable to common stockholders of $3.6 million.
Operating income increased 64% to $6.9 million, and basic EPS improved to $0.04; diluted EPS was $0.03.
Nine-month revenue reached $79.4 million, with net income of $11.2 million and cash and equivalents totaling $80.3 million as of September 30, 2025.
Commercial launches of Etorel® and Contiva® in 2025 contributed to revenue growth and market expansion.
Financial highlights
Q3 2025 revenue: $30.6 million (up from $25.5 million in Q3 2024); nine-month revenue: $79.4 million (up from $77.9 million in 2024).
Q3 2025 gross profit: $28.9 million (18% increase); nine-month gross profit: $75.7 million (1% increase).
Q3 net income: $5.9 million (vs. $2.9 million prior year); adjusted net income: $8.8 million.
Q3 2025 EPS: $0.04 basic, $0.03 diluted; nine-month EPS: $0.08 basic, $0.04 diluted.
Operating income for Q3 2025: $6.9 million (64% increase); nine-month operating income: $11.4 million (down 27%).
Outlook and guidance
Full-year revenue guidance revised to $115–118 million (from $118–128 million) due to delayed Etorel® rollout and procurement uncertainty.
Anticipates continued revenue growth in Q4 2025, driven by expansion of new product franchises and refocused marketing on ETUARY®.
Plans to file a New Drug Application for Hydronidone in the PRC and initiate a Phase 2 trial in the U.S. in 2026.
Guidance assumes constant currency and no major economic disruptions.
Ongoing investment in commercialization and R&D to support long-term growth.
Impact of MASH market dynamics on Hydronidone US IND
Elaborate on Etorel/Contiva sales challenges
ETUARY sales: Q3 recovery vs 9-month decline
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Gyre Therapeutics earnings date
Q4 202517 Mar, 2026
Next Gyre Therapeutics earnings date
Q4 202517 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Gyre Therapeutics Inc., formerly known as Catalyst Biosciences, Inc., is a biopharmaceutical company engaged in the development and commercialization of therapies for organ fibrosis and inflammatory diseases. The company's main focus is on the development of Hydronidone (F351), a therapeutic aimed at treating Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis), previously known as Nonalcoholic Steatohepatitis (NASH). The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage